ReviewFrontiers in oncology2026
Research progress of small molecule targeted drugs for non-small cell lung cancer.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-small cell lung cancer (NSCLC) constitutes approximately 85% of all lung cancer cases and remains a major clinical challenge with a poor overall prognosis. Molecular targeted therapy has thus emerged as a cornerstone of its treatment. This review summarizes the research progress of advances in small-molecule targeted agents against major driver oncogenes in NSCLC, including epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and Kirsten rat sarcoma viral oncogene homolog (KRAS). We elaborate on the mechanism of action, clinical efficacy and treatment-related adverse events (TRAEs) of each generation of inhibitors, while updating the developmental status of innovative therapies and emerging. Notably, this article further integrates clinical data of investigational small-molecule targeted drugs that address emerging oncogenic drivers such as rat sarcoma viral oncogene homolog (RAS), human epidermal growth factor receptor 2 (HER2), and v-src avian sarcoma viral oncogene homolog (SRC), which have demonstrated promising clinical activity in early-phase trials. These findings highlight potential avenues for future development of NSCLC-targeted therapies. Despite iterative optimization across multiple generations, current targeted drugs for NSCLC still face prominent limitations, including acquired drug resistance and insufficient penetration across the blood-brain barrier (BBB). Moving forward, future research should prioritize accelerating the clinical translation of investigational drugs, exploring combination treatment regimens, identifying novel molecular targets, and optimizing the overall system of molecular targeted therapy. These efforts will help further improve clinical outcomes for patients with NSCLC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.